Stroke Anticoagulation and Prophylaxis: Follow-up

References

1. Adams HP, Bendixen BH, Leira E, et al. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. Jul 13 1999;53(1):122-5. [Medline]. [Full Text].

2. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. Apr 8 2000;355(9211):1205-10. [Medline].

3. Kalafut MA, Gandhi R, Kidwell CS, Saver JL. Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia. Stroke. Nov 2000;31(11):2563-8. [Medline]. [Full Text].

4. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. Apr 7 2004;43(7):1201-8. [Medline].

5. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. Jan 21 2004;43(2):241-7. [Medline].

6. [Guideline] Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. Sep 5 2006;48(5):e247-346. [Medline].

7. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. Aug 11 2007;370(9586):493-503. [Medline].

8. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. Feb 9 2005;293(6):690-8. [Medline].

9. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. Nov 22 2003;362(9397):1691-8. [Medline].

10. Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. Aug 18 2009;[Medline].

11. Sandercock PA, Gibson LM, Liu M. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. Apr 15 2009;CD000248. [Medline].

12. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. Dec 1 1999;282(21):2058-67. [Medline].

13. Thenappan T, Ali Raza J, Movahed A. Aortic atheromas: current concepts and controversies-a review of the literature. Echocardiography. Feb 2008;25(2):198-207. [Medline].

14. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol. Dec 1997;42(6):857-65. [Medline].

15. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. Nov 15 2001;345(20):1444-51. [Medline].

16. The ESPRIT Study Group; Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. Feb 2007;6(2):115-24. [Medline].

17. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. Mar 31 2005;352(13):1305-16. [Medline].

18. [Guideline] Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. May 2008;39(5):1647-52. [Medline]. [Full Text].

19. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. Feb 4 2004;291(5):576-84. [Medline].

20. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. Sep 18 2003;349(12):1133-8. [Medline].

21. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. May 2005;3(5):848-53. [Medline].

22. [Best Evidence] Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. Mar 1 2006;295(9):1050-7. [Medline].

23. [Best Evidence] Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener HC. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke. Mar 2007;38(3):874-80. [Medline].

24. [Guideline] Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. Jan 15 2008;51(2):210-47. [Medline].

25. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. Jul 11 1994;154(13):1449-57. [Medline].

26. Baker WF, Bick RL. Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost. 1999;25(4):387-406. [Medline].

27. Bath PM, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke : a meta-analysis of randomized controlled trials. Stroke. Jul 2000;31(7):1770-8. [Medline].

28. Baumgartner RW, Studer A, Arnold M, Georgiadis D. Recanalisation of cerebral venous thrombosis. J Neurol Neurosurg Psychiatry. Apr 2003;74(4):459-61. [Medline].

29. Benesch CG, Chimowitz MI. Best treatment for intracranial arterial stenosis? 50 years of uncertainty. The WASID Investigators. Neurology. Aug 22 2000;55(4):465-6. [Medline].

30. Bertram M, Bonsanto M, Hacke W, Schwab S. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol. Mar 2000;247(3):209-14. [Medline].

31. Bogousslavsky J, Kaste M, Skyhoj Olsen T, et al. Risk factors and stroke prevention. European Stroke Initiative (EUSI). Cerebrovasc Dis. 2000;10 Suppl 3:12-21. [Medline].

32. [Guideline] Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. Sep 23 2008;52(13):e1-142. [Medline].

33. Brandt T, Caplan L. Spontaneous Arterial Dissection. Curr Treat Options Neurol. Sep 2001;3(5):463-469. [Medline].

34. Cairns JA, Théroux P, Lewis HD Jr, et al. Antithrombotic agents in coronary artery disease. Chest. Jan 2001;119(1 Suppl):228S-252S. [Medline].

35. Cauli C, Barcellona D, Marongiu F. Oral anticoagulant therapy in the primary and secondary prophylaxis of stroke. Ital Heart J. Nov 2003;4(11):755-67. [Medline].

36. Chaves CJ, Caplan LR. Heparin and oral anticoagulants in the treatment of brain ischemia. J Neurol Sci. Feb 1 2000;173(1):3-9. [Medline].

37. Ezekowitz JA, Straus SE, Majumdar SR, McAlister FA. Stroke: strategies for primary prevention. Am Fam Physician. Dec 15 2003;68(12):2379-86. [Medline].

38. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. Mar 24-31 1999;281(12):1112-20. [Medline].

39. [Guideline] Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. [Medline].

40. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. Jul 15 2003;109 Suppl 1:S9-15. [Medline].

41. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke. Nov 2002;33(11):2722-7. [Medline].

42. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. May 2008;39(5):1482-6. [Medline]. [Full Text].

43. Koga M, Saku Y, Toyoda K, et al. Reappraisal of early CT signs to predict the arterial occlusion site in acute embolic stroke. J Neurol Neurosurg Psychiatry. May 2003;74(5):649-53. [Medline].

44. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest. Nov 1998;114(5 Suppl):579S-589S. [Medline].

45. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. Dec 13 2001;345(24):1740-6. [Medline].

46. Pessin MS, Adams HP, Adams RJ, et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Acute interventions. Stroke. Jul 1997;28(7):1518-21. [Medline].

47. Pessin MS, Estol CJ, Lafranchise F, Caplan LR. Safety of anticoagulation after hemorrhagic infarction. Neurology. Jul 1993;43(7):1298-303. [Medline].

48. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Stroke prevention in patients with nonvalvular atrial fibrillation. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. Sep 1998;51(3):671-3. [Medline].

49. Ringelstein EB, Nabavi D. Long-term prevention of ischaemic stroke and stroke recurrence. Thromb Res. May 1 2000;98(3):83-96. [Medline].

50. Sherman DG. Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: what is the next step?. Cerebrovasc Dis. 2004;17 Suppl 1:138-43. [Medline].

51. Zweifler RM. Management of acute stroke. South Med J. Apr 2003;96(4):380-5. [Medline].

Further Reading

Keywords

cerebral ischemia, ischemic thromboembolic stroke, anticoagulants, anticoagulation therapy, anticoagulant, anticoagulant therapy, blood coagulation, heparin, heparin analogues, warfarin

Contributor Information and Disclosures

Author

Uwe Walter, MD, PhD, Associate Professor, Department of Neurology, University Hospital of Rostock, Germany; Director Neurological Intensive Care Unit and Stroke Unit, Head of Neurosonological Lab
Disclosure: Nothing to disclose.

Medical Editor

Draga Jichici, MD, FRCP, Associate Clinical Professor, Department of Medicine, Division of Neurology and Critical Care Medicine, McMaster University, Canada
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Howard S Kirshner, MD, Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center
Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association
Disclosure: Boehringer Ingelheim Honoraria Speaking and teaching; BMS/Sanofi Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Helmi L Lutsep, MD, Professor, Department of Neurology, Oregon Health & Science University; Associate Director, Oregon Stroke Center
Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association
Disclosure: Co-Axia Consulting fee Review panel membership; Talecris Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Boehringer Ingelheim Honoraria Speaking and teaching; Concentric Medical Consulting fee Review panel membership; Abbott Consulting fee Consulting; Sanofi  Consulting